Fig. 3From: Liposomal formulations of carboplatin injected by convection-enhanced delivery increases the median survival time of F98 glioma bearing ratsKaplan–Meier survival curve of F98 glioma bearing rats treated with CED of different carboplatin formulations. Cationic liposomes L1 and L2 improved median survival times (35 days for non-pegylated L1, 29 days for pegylated L2) when compared to control (dextrose 5%) (23.5 days), but shorter or equivalent survival time when compared to free carboplatin (38.5 days). Anionic pegylated liposomal carboplatin L4 offered the best median survival time (49.5 days) and showed a better median survival time than free carboplatin. Injection with the empty anionic pegylated liposome L4′ didn’t improved the median survival time (25 days) which was similar to animals injected with dextrose 5%. Log Rank test p value compared to 5% dextrose: L1, p < 0.0001; L2, p = 0.0018; L3, p = 0.0003; L4, p < 0.0001; L4′, p = 0.447 (p = 0.0001, when compared to L4), free carboplatin, p < 0.0001Back to article page